AVEYABEK Trademark
Trademark Overview
On Wednesday, September 4, 2024, a trademark application was filed for AVEYABEK with the United States Patent and Trademark Office. The USPTO has given the AVEYABEK trademark a serial number of 98733166. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Thursday, March 5, 2026. This trademark is owned by Celgene Corporation. The AVEYABEK trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; anticoagulants for human use; Pharmaceutical preparations f...
General Information
| Serial Number | 98733166 |
| Word Mark | AVEYABEK |
| Filing Date | Wednesday, September 4, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Thursday, March 5, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, March 24, 2026 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressant preparations, pharmaceutical antibodies for medical use, and immunotherapy preparations for the treatment of cancer; cytokine inhibitory drugs for human use being pharmaceutical preparations for the treatment of cancer; anticoagulants for human use; Pharmaceutical preparations for human use that modulate the immune system for the treatment of immune-system related diseases and disorders; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy preparations for the treatment of cancer; Pharmaceutical and biological preparations for human use, namely, stem cells for medical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use; Pharmaceutical preparations for human use for the treatment of neuropsychiatric disorders; therapeutic radiopharmaceutical preparations for human use for the treatment of cancer and solid tumors; diagnostic radiopharmaceutical preparations for human use; diagnostic preparations for human use for medical purposes; radiopharmaceutical preparations for human use in the nature of imaging and detection agents for diagnosing and monitoring cancer; biological preparations for human use in the nature of radio-isotope markers for therapeutic or diagnostic use; Pharmaceutical preparations for human use for the treatment of cystic fibrosis. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Wednesday, September 4, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Celgene Corporation |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Princeton, NJ 08543
US |
Trademark Events
| Event Date | Event Description |
| Wednesday, September 4, 2024 | NEW APPLICATION ENTERED |
| Friday, March 14, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Saturday, March 15, 2025 | ASSIGNED TO EXAMINER |
| Thursday, March 27, 2025 | ASSIGNED TO EXAMINER |
| Thursday, March 27, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, March 27, 2025 | NON-FINAL ACTION E-MAILED |
| Thursday, March 27, 2025 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, June 25, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, June 25, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, June 25, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Tuesday, March 3, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 18, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
